MRK
Merck & Co., Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$146.53
+1.29%Nov 3, 2026, 21:13 UTC
The US Food and Drug Administration granted Merck & Co., Inc. emergency use authorization for a treatment for screwworm in dogs.
Source:Nov 3, 2026, 11:45 UTC
Merck & Co., Inc. announced the initiation of the Phase 3 ENHANCE-3 trial evaluating Ohtuvayre (ensifentrine) to prevent COPD exacerbations in adults receiving standard of care, with recruitment underway.
Source:Oct 30, 2026, 18:21 UTC
Merck & Co., Inc. shares traded higher on Friday amid a continued rally.
Source:Oct 29, 2026, 21:31 UTC
Law Offices of Frank R. Cruz announced an investigation into potential securities fraud claims involving Merck & Co., Inc.
Source:Oct 29, 2026, 15:02 UTC
Merck shares rose 5.29% to $148.39.
Source:Oct 29, 2026, 11:47 UTC
Merck & Co. reported third-quarter 2026 revenue of $18.085 billion, net income of $5.065 billion and diluted EPS of $2.04, and provided FY2026 EPS guidance of $2.77 to $2.82.
Oct 29, 2026, 10:37 UTC
Merck raised its full-year revenue and adjusted earnings-per-share guidance.
Source:Oct 29, 2026, 10:35 UTC
Merck's shares rose 2.7% in premarket trading.
Source:Oct 29, 2026, 10:35 UTC
Merck's third-quarter results exceeded expectations.
Oct 27, 2026, 10:00 UTC
China’s National Medical Products Administration accepted Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.’s marketing application for an additional indication of sac-TMT in combination with pembrolizumab as first-line treatment for certain adults with advanced or metastatic non-squamous non-small cell lung cancer.
Source:Oct 26, 2026, 18:30 UTC
Merck reported late-stage trial results showing that sacituzumab tirumotecan extended median survival to 19 months versus 12.1 months with chemotherapy in advanced endometrial cancer.
Source:Oct 26, 2026, 10:41 UTC
Hong Kong Science and Technology Parks Corporation and Merck & Co., Inc. signed a strategic cooperation agreement to establish the Merck & Co., Inc. Hong Kong Centre at Hong Kong Science Park and collaborate on training, innovation scouting and an annual innovation event.
Source:Oct 25, 2026, 19:30 UTC
Moderna, Inc. and Merck released detailed results from a late-stage trial showing that adding personalized intismeran to Keytruda reduced the two-year risk of melanoma recurrence by 42% compared with Keytruda alone.
Source:Oct 23, 2026, 22:30 UTC
EV-309, a Phase 3 trial of enfortumab vedotin plus pembrolizumab versus concurrent chemoradiotherapy for bladder preservation in muscle-invasive bladder cancer, was presented at the 2026 ESMO meeting.
Source:Oct 23, 2026, 04:51 UTC
Moderna, Inc. shares fell as much as 25% on Thursday despite positive cancer-vaccine data, while remaining up more than 530% for 2026 as of Thursday afternoon.
Oct 22, 2026, 23:59 UTC
Moderna, Inc. and Merck & Co., Inc. announced Phase 3 trial results showing that their mRNA cancer vaccine combined with Keytruda reduced the risk of melanoma recurrence or death by 42% and the risk of cancer spreading by 38%.
Oct 22, 2026, 09:24 UTC
China's National Medical Products Administration approved Merck's belzutifan tablets for patients aged 12 and older with locally advanced, unresectable or metastatic pheochromocytoma or paraganglioma.
Source:Oct 19, 2026, 13:40 UTC
Halper Sadeh LLC said it is investigating whether Silence Therapeutics plc and its board obtained a fair price in the company's sale to Merck & Co., Inc. for $20.00 in cash per American Depositary Share.
Source:Oct 16, 2026, 18:00 UTC
Merck & Co., Inc. reported $18.8 billion in US revenue for Keytruda in 2025 and $22.5 billion in profits, up 16% from 2024.
Source:Oct 15, 2026, 15:00 UTC
Technology shares fell in Thursday premarket trading, including CoreWeave, Inc. down about 5%, ORACLE CORP down about 2%, MICRON TECHNOLOGY INC down nearly 4%, ADVANCED MICRO DEVICES INC down more than 2%, and NVIDIA CORP down around 2%; Walmart Inc. gained about 3% and Merck & Co., Inc. advanced more than 1%.
Source:Oct 13, 2026, 16:43 UTC
Merck & Co. announced the election of Paul J. Diaz to its board of directors, effective November 1, 2026.
Oct 13, 2026, 10:45 UTC
Merck & Co., Inc. announced that results from three pivotal clinical trials and more than 90 additional abstracts will be presented at the ESMO Congress 2026 in Madrid from October 23 to 27.
Source:Oct 12, 2026, 16:51 UTC
Tempus AI, Inc. expanded its strategic collaborations with Moderna, Inc., Merck & Co., Inc. and RECURSION PHARMACEUTICALS, INC. to advance its precision medicine business.
Source:Oct 10, 2026, 22:10 UTC
Merck & Co., Inc. presented one-year results from the pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig in adults with diabetic macular edema.
Oct 9, 2026, 14:44 UTC
The U.S. National Institutes of Health reportedly plans to accelerate cancer-vaccine development and clinical trials through a public-private initiative expected to begin in December.
Source:Oct 7, 2026, 12:30 UTC
Merck & Co., Inc. found Merck to infringe Halozyme's EP 2,797,622 patent and enjoined MSD AG from manufacturing, marketing, using, importing or stocking Keytruda SC in eight European markets.
Sep 12, 2026, 18:00 UTC
Tempus partnered with Merck on AI-driven precision medicine.
Source:
Page 1Next →